dopamine hydrochloride injection, solution, concentrate
general injectables & vaccines, inc - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hydrochloride 40 mg in 1 ml - dopamine hcl is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. patients most likely to respond adequately to dopamine hcl are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine hcl, the better the prognosis. where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine hcl. poor perfusion of vital organs – urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. nevertheless, the physician should also observe the
dopamine hydrochloride injection, solution, concentrate
hospira, inc. - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hydrochloride 40 mg in 1 ml - dopamine hcl injection is indicated to improve hemodynamic status in patients in distributive shock or shock due to reduced cardiac output. dopamine is contraindicated in patients with pheochromocytoma. risk summary there are no human data with dopamine use in pregnant women. there are risks to the mother and fetus from hypotension associated with shock, which can be fatal if left untreated (see clinical considerations ). in animal reproduction studies, adverse developmental outcomes were observed with intravenous dopamine hcl administration in pregnant rats during organogenesis at doses, on a mcg/m2 basis, of one‑third the human starting dose of 2 mcg/kg/minute (90 mcg/m2 /minute). the background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies carry some risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2‑4% and 15‑20%,
aggrastat 12.5mg/50ml concentrate for solution for infusion vials
correvio uk ltd - tirofiban - solution for infusion - 250microgram/1ml
aciclovir 25mg/ml concentrate for solution for infusion
pfizer healthcare ireland - aciclovir sodium; aciclovir sodium - concentrate for solution for infusion - 25 milligram(s)/millilitre - nucleosides and nucleotides excl. reverse transcriptase inhibitors; aciclovir
dexmedetomidine kalceks concentrate for solution for infusion
kalceks jsc - dexmedetomidine (dexmedetomidine hydrochloride) - concentrate for solution for infusion - 100mcg/ml
noradrenaline concentrate for solution for infusion
kalceks jsc - noradrenaline (noradrenaline tartrate) - concentrate for solution for infusion - 1mg/ml
noradrenaline concentrate for solution for infusion
kalceks jsc - noradrenaline tartrate - concentrate for solution for infusion - 1mg/ml
dexmedetomidine kalceks concentrate for solution for infusion
kalceks jsc - dexmedetomidine (dexmedetomidine hydrochloride) - concentrate for solution for infusion - 100mcg/ml
noradrenaline concentrate for solution for infusion
kalceks jsc - noradrenaline (noradrenaline tartrate) - concentrate for solution for infusion - 1mg/ml
noradrenaline concentrate for solution for infusion
kalceks jsc - noradrenaline tartrate - concentrate for solution for infusion - 1mg/ml